Toronto, Ontario–(Newsfile Corp. – September 2, 2024) – Britannia Life Sciences Inc. (CSE: BLAB) (“Britannia” or the “Company“) is pleased report its financial results for the year ended March 31, 2024. The Company’s audited annual financial statements and related management’s discussion and analysis for the year ended March 31, 2024, are available for review on SEDAR+ (www.sedarplus.ca) under the Company’s issuer profile.
Financial highlights for the financial year ended March 31, 2024, include (all amounts are presented in Canadian dollars unless otherwise stated):
Significant corporate developments during Q4 2024 and subsequent to the end of the fourth quarter, include:
Peter Shippen, Chief Executive Officer of the Company, commented: “We are pleased with the continued progress made by the group during the 2024 fiscal year. The financial performance of our core consumer products business continues to improve and provide cash flow for future growth and development. The Company anticipates the reversal of losses in its equity investment in BMS in fiscal 2025 as the first PhotonAssayTM units begin to operate at capacity “.
About Britannia Life Sciences Inc.
Britannia Life Sciences Inc. is focused on introducing cutting-edge technologies into the traditional laboratory and regulatory platforms to power data-driven insights to improve the outcomes of its customers. Britannia’s services, including product formulations, safety assessments, analytical and microbiological testing, global compliance, and consumer evaluations are offered to companies ranging from multinationals to startups particularly in the cosmetics, food, and wellness industries. Britannia also provides geochemical testing and analysis to the natural resources industry through its subsidiary Britannia Mining Solutions. Britannia Mining Solutions operates a geochemical laboratory in the United States and is in the process of rolling out 12 PhotonAssay™ machines globally, with two PhotonAssayTM units installed and commissioned to-date.
Britannia’s head office is located at 120 Adelaide Street West, Suite 2400, Toronto, Ontario, M5H 1T1.
For further information contact:
Britannia Life Sciences Inc.
Email: investors@britannia.life
Forward-Looking Information
This news release may contain certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation regarding Britannia and its business including, but not limited to, the delay in making its Annual Filings, the PhotonAssayTM being adopted by the world’s largest and most respected mining companies; PhotonAssayTM becoming the future industry benchmark for mineral analysis; and the Company’s ability to deploy additional PhotonAssayTM units worldwide over the next year. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates”, or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes”, or intends”, or variations of such words and phrases or stating that certain actions, events or results “may”, or “could”, “would”, “might”, or “will”, be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Except as required by law, Britannia assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. The reader is cautioned not to place undue reliance on forward-looking statements.
For a detailed description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s most recet management discussion and analysis and annual financial statements, copies of which are available on SEDAR+ under the Company’s profile at www.sedarplus.ca.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221871
NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…
Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel…
Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…